-
Mashup Score: 26Predictors of unsustained measurable residual disease negativity in patients with multiple myeloma - 6 hour(s) ago
Amp(1q), HRCA ≥2, high CTC levels, and a longer time to reach first MRD negativity are significant predictors of unsustained MRD negativity.Maintenance treatmen
Source: ashpublications.orgCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 1Another quadruplet therapy for multiple myeloma: the beginning of the end for autologous haematopoietic stem-cell transplantation? - 12 hour(s) ago
In the past 15 years, treatment frameworks for newly diagnosed multiple myeloma have radically changed. It is important to recall that as recently as 2010, Rajkumar and colleagues1 presented ECOG E4A03, which was a phase 3 trial examining the role of lenalidomide, combined with two different dosing regimens for dexamethasone, that showed a 68% overall response rate (ORR; 10% complete remission rate) after four cycles of therapy, a result considered to be astounding at the time. Fast forward to 2024, the use of triplet induction has nearly been supplanted by four component regimens, typically including an immunomodulatory drug, a proteasome inhibitor, a steroid, and the newest addition, an anti-CD38 antibody.
Source: www.thelancet.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 7
Although the study did not achieve the prespecified complete response threshold, Isa-KRd induced deep and durable responses in transplant-eligible patients with newly diagnosed multiple myeloma. The treatment proved safe and consistent with similar regimens in this setting.
Source: www.thelancet.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 105Daratumumab-based quadruplet therapy for transplant-eligible newly diagnosed multiple myeloma with high cytogenetic risk - 1 day(s) ago
Blood Cancer Journal – Daratumumab-based quadruplet therapy for transplant-eligible newly diagnosed multiple myeloma with high cytogenetic risk
Source: www.nature.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 5GPRC5D-Targeted Therapy Continues to be Effective After Dose Reduction in R/R Multiple Myeloma - 2 day(s) ago
At a live virtual event, Leyla Shune, MD, discussed the emergence of talquetamab-tgvs for patients with relapsed/refractory multiple myeloma.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 103Daratumumab-based quadruplet therapy for transplant-eligible newly diagnosed multiple myeloma with high cytogenetic risk - 3 day(s) ago
Blood Cancer Journal – Daratumumab-based quadruplet therapy for transplant-eligible newly diagnosed multiple myeloma with high cytogenetic risk
Source: www.nature.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 34B‐cell maturation antigen‐based therapies post‐talquetamab in relapsed or refractory multiple myeloma - 3 day(s) ago
eJHaem is a Gold open access haematology journal of the British Society for Haematology, publishing practice and research papers applicable to a worldwide readership.
Source: onlinelibrary.wiley.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 41
PURPOSE Outcomes for patients with newly diagnosed multiple myeloma (NDMM) are heterogenous, with overall survival (OS) ranging from months to over 10 years. METHODS To decipher and predict the molecular and clinical heterogeneity of NDMM, we assembled a series of 1,933 patients with available clinical, genomic, and therapeutic data. RESULTS Leveraging a comprehensive catalog of genomic drivers, we identified 12 groups, expanding on previous gene expression–based molecular classifications. To build a model predicting individualized risk in NDMM (IRMMa), we integrated clinical, genomic, and treatment variables. To correct for time-dependent variables, including high-dose melphalan followed by autologous stem-cell transplantation (HDM-ASCT), and maintenance therapy, a multi-state model was designed. The IRMMa model accuracy was significantly higher than all comparator prognostic models, with a c-index for OS of 0.726, compared with International Staging System (ISS; 0.61), revised-ISS (0
Source: ascopubs.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 45MRD as an endpoint for accelerating drug approval in multiple myeloma: updates from the ODAC meeting - 4 day(s) ago
On 12th April 2024, a meeting of the US Food and Drug Administration’s (FDA) Oncologic Drugs Advisory Committee (ODAC) was held to assess the use of measurable residual disease (MRD) as a regulatory endpoint to accelerate the approval of novel therapies in multiple myeloma (MM). Ola Landgren, MD, PhD, Sylvester Comprehensive Cancer Center, Miami, FL, shares an insight into the meeting, during which his team from the Sylvester Comprehensive Cancer Center, the i2TEAMM, and the FDA gave three presentations on data supporting the use of MRD as a surrogate endpoint. Following this, all 12 ODAC members present voted ‘for’ the use of MRD as ‘an endpoint reasonably likely to predict clinical benefit’. Prof. Landgren highlights that this is a milestone in the field of myeloma and will accelerate the drug approval process by a factor of two to three, saving many years of patients’ lives and allowing for the development of curative therapies. This interview took place at the 17th International Wo
Source: www.vjhemonc.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 8
Cilta-cel has received approval from the European Commission for multiple myeloma that is relapsed or refractory to at least 1 prior line of therapy.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
Excellent FORTE #MMsm work by @Dagostino_MD and colleagues, now in @BloodJournal! Even among MRD "neg" pts (10^-5), taking foot off gas pedal means slightly higher risk of MRD resurgence (≠ relapse, to be clear). But stopping K after 2 yrs might work! https://t.co/XHQt71VEDH https://t.co/tBMVoqiUfz